1. Home
  2. MCD vs NVO Comparison

MCD vs NVO Comparison

Compare MCD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MCD

McDonald's Corporation

N/A

Current Price

$324.86

Market Cap

233.3B

ML Signal

N/A

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

N/A

Current Price

$38.79

Market Cap

269.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MCD
NVO
Founded
1940
1923
Country
United States
Denmark
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.3B
269.6B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
MCD
NVO
Price
$324.86
$38.79
Analyst Decision
Buy
Hold
Analyst Count
28
11
Target Price
$342.21
$51.00
AVG Volume (30 Days)
3.1M
19.0M
Earning Date
05-14-2026
01-01-0001
Dividend Yield
2.27%
3.18%
EPS Growth
4.92
N/A
EPS
11.95
N/A
Revenue
$26,885,000,000.00
N/A
Revenue This Year
$8.05
N/A
Revenue Next Year
$5.72
$3.30
P/E Ratio
$27.49
$13.60
Revenue Growth
3.72
N/A
52 Week Low
$283.47
$35.85
52 Week High
$341.75
$82.23

Technical Indicators

Market Signals
Indicator
MCD
NVO
Relative Strength Index (RSI) 46.72 34.16
Support Level $320.15 $35.85
Resistance Level $335.67 $50.30
Average True Range (ATR) 4.74 0.87
MACD -1.57 0.27
Stochastic Oscillator 17.43 24.62

Price Performance

Historical Comparison
MCD
NVO

About MCD McDonald's Corporation

McDonald's is the world's largest restaurant brand, with nearly $131 billion in systemwide sales across more than 44,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 61%), with the remainder stemming from company-operated restaurants across three segments: the United States (41% of systemwide sales), international operated markets (34%), and international developmental/licensed markets (25%).

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: